James Hsieh.jpg

James J. Hsieh, MD, PhD

Department of Medicine
Oncology Division
Molecular Oncology
Medical Oncology

Clinical Interests

  • Kidney cancer

Research Interests

  • Kidney cancer metabolomics
  • Genomics, Epigenetics
  • Therapeutics, Precision Medicine
  • Translational kidney cancer research
  • Mouse tumor models, Mouse development
  • Drug development
  • Taspase1, Notch, MLL, Stem cells


  • 314-273-1688 (lab)
  • 314-454-8681 (clinic)
  • 314-362-7086 (fax)
  • 554 McDonnell Medical Sciences Building (office/lab)
  • Division of Oncology
    Campus Box 8069
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110


As a medical student taking care of cancer patients in 1990, Dr. James Hsieh witnessed the hopelessness that devastated metastatic cancer patients and decided to devote his life to the fight against cancer. His Ph.D. thesis concluded the mechanisms by which EBV EBNA2 hijacks the cellular Notch signaling for tumorigenesis and earned him the Young Investigator Award at Johns Hopkins Medical School in 1996. Dr. Hsieh entered Washington University for Internal Medicine training and then Dana Farber Cancer Institute at Harvard Medical School for Oncology training. Dr. Hsieh studied under the late Dr. Korsmeyer as an HHMI Physician-Scientist Fellowship Awardee in 2000-2003. He discovered proteolytic processing of MLL, purified the protease, and named it "Taspase1". As NCI K01 Howard Temin Awardee, Dr. Hsieh joined the faculty at Wash U. in 2004. Dr. Hsieh was inducted into ASCI in 2010 and is the principal investigator of an NCI Experimental Therapeutics (NExT) project "Optimization of Lead Small Molecule Taspase1 Inhibitors for Cancer Therapeutics". As a physician scientist taking care of metastatic kidney cancer patients, Dr. Hsieh relocated in 2010 and founded the MSK translational kidney cancer research program. His laboratory employs state-of-art platforms and utilizes clinical trial materials to integrate kidney cancer genomics, transcriptomics, proteomics, metabolomics, and therapeutics; pioneers a novel metabolic analytic algorithm (Metabologram) to interrogate human cancer metabolism; generates novel kidney cancer mouse models recapitulating human kidney cancer mutations; proposes a novel cancer evolution (Braided Cancer River) mode; and discovers genomic biomarkers to predict response to targeted therapies. In 2017, Dr. Hsieh returned to Washington University to incorporate novel clinical trial concepts to further expand his kidney cancer research program. His primary translational goals are to develop novel mechanism-based, personalized therapeutics to prevent cancer recurrence in high-risk kidney cancer patients and provide cure to significant number of metastatic kidney cancer patients by 2025.